Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00756717 · ClinicalTrials.gov registry record · Phase 4

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer

A Phase 4 study of Breast Cancer, sponsored by Loyola University.

Completed
Registry status
Phase 4
Development phase
22
Enrollment target
1
Study location

NCT00756717: Completed Phase 4 study of Breast Cancer, sponsored by Loyola University.

NCT00756717 is a Phase 4 study of Breast Cancer that has completed, run by Loyola University. The registered enrollment target is 22 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00756717, a Phase 4 study of Breast Cancer, has completed, sponsored by Loyola University.

COMPLETED
Registry status
Phase 4
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research project is to study the effect of a research (investigational) drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells. Tamoxifen and letrozole are standard hormone treatments used to treat breast cancers that are positive for the estrogen receptor. However, over time the breast cancer cells can become resistant to tamoxifen and letrozole. MK-0752 is in a class of drugs called gamma secretase inhibitors. Gamma secretase inhibitors may play a role in reversing the resistance to drugs such as tamoxifen and letrozole.

Primary Outcome

The number of participants experiencing at least one adverse event during the 24-day observation period and initial post-operative visit.

Conditions Studied

Interventions

  • DRUG MK-0752

Study Locations (1)

Illinois

  • Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center - Maywood

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2008-02-14
Est. Completion 2011-12-21
Phase Phase 4
Loyola University

92 total trials

What the finished NCT00756717 record still lists

NCT00756717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-0752 is the first listed.

NCT00756717 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00756717 about?

NCT00756717 is a clinical study titled "Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer". The purpose of this research project is to study the effect of a research (investigational) drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells. Tamoxifen and letrozole are standard hormone treatments used to treat breast cancers that are positive for the estrogen recep...

What is the current status of trial NCT00756717?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2008-02-14. Estimated completion is 2011-12-21.

What conditions does trial NCT00756717 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00756717?

The interventions under investigation include: MK-0752 (DRUG).

Who is sponsoring clinical trial NCT00756717?

This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00756717 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00756717's enrollment target sits among peer trials

22 1063rd of 1224 higher than 153 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00756717, the US trial registry maintained by the National Library of Medicine. NCT00756717 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.